Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01134900
Other study ID # 081002
Secondary ID R01LM009965
Status Completed
Phase N/A
First received May 27, 2010
Last updated January 25, 2012
Start date June 2010
Est. completion date August 2010

Study information

Verified date January 2012
Source Vanderbilt University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The utilization of clinical decision support (CDS) is increasing among healthcare facilities which have implemented computerized physician order entry or electronic medical records. Formal prospective evaluation of CDS implementations occurs rarely, and misuse or flaws in system design are often unrecognized. Retrospective review can identify failures but is too late to make critical corrections or initiate redesign efforts. A real-time surveillance dashboard for high-alert medications integrates externalized CDS interactions with relevant medication ordering, administration, and therapeutic monitoring data. The surveillance view of the dashboard displays all currently admitted, eligible patients and provides brief demographics with triggering order, laboratory, and CDS failure data to allow prioritization of high-risk scenarios. The patient detail view displays a detailed timeline of orders, order administrations, laboratory values, and CDS interactions for an individual patient and allows users to understand provider actions and patient condition changes occurring in conjunction with CDS failures. Clinical pharmacists' use of the dashboard for patient monitoring and intervention aims to increase the rate and timeliness of intercepted medication errors compared to CPOE-based CDS in the setting of acute kidney injury, which affects patients at various points across all hospital units and services and has numerous opportunities for intervention.


Recruitment information / eligibility

Status Completed
Enrollment 540
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 0.5 mg/dl increase or decrease in serum creatinine within 48 hours

- Active, recurring order for targeted renally cleared or nephrotoxic medication

Exclusion Criteria:

- Chronic dialysis

- Transplant patients

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Other:
Pharmacy Dashboard Review and Intervention
Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.

Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University National Library of Medicine (NLM)

Country where clinical trial is conducted

United States, 

References & Publications (1)

McCoy AB, Peterson JF, Gadd CS, Danciu I, Waitman LR. A system to improve medication safety in the setting of acute kidney injury: initial provider response. AMIA Annu Symp Proc. 2008 Nov 6:1051. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Drug Events or Potential Adverse Drug Events Our primary outcome measured the rate of AKI-related ADEs and pADEs. We defined pADEs as incidents with the potential for injury related to a drug, such as use of a non-steroidal anti-inflammatory drug for at least 24 hours, and ADEs as injuries resulting from the administration of a drug, such as a toxic vancomycin trough level or a bleed after administration of enoxaparin. We measured outcomes after completion of the inpatient encounter (either by death or discharge); pADEs or ADEs occurring after patient discharge were not included in the analysis. Until patient discharge (~2 week average) Yes
Secondary Time to Provider Response Time from study event to modification or discontinuation of targeted medication Until patient discharge (~2 week average) Yes
See also
  Status Clinical Trial Phase
Completed NCT00982527 - Fenoldopam in Pediatric Cardiac Surgery Phase 3
Completed NCT00908843 - Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration N/A
Completed NCT00654992 - Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery Phase 2/Phase 3
Completed NCT05407272 - Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care N/A
Not yet recruiting NCT05399420 - Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT04072432 - A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease Phase 1
Recruiting NCT00230412 - Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study) N/A
Completed NCT00148044 - Uremic Toxins of Patients With Acute Kidney Failure N/A
Active, not recruiting NCT04450095 - Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery Phase 2
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03353389 - Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
Completed NCT03727581 - Ultrasound for Guidewire Detection
Completed NCT00912184 - Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure Phase 1/Phase 2
Recruiting NCT00522756 - Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy Phase 3
Completed NCT00484354 - Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery Phase 2
Terminated NCT00316576 - Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA) N/A
Completed NCT00122018 - An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery Phase 2
Unknown status NCT01359722 - N-acetylcysteine to Prevent Renal Failure N/A
Completed NCT00286273 - Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration Phase 4